SCHEMBL213883

SCHEMBL213883

COc1ccc2nc(NC(=O)NCc3ccc(C(=O)O)cc3)sc2c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 5/20 0.78
SCD O00767 8/20 0.70
NPC1 O15118 5/20 0.62
RAB9A P51151 5/20 0.62
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
CSNK1D P48730 2/20 0.62
LMNA P02545 1/20 0.62
POLB P06746 1/20 0.62
MAPT P10636 1/20 0.62
NFKB1 P19838 1/20 0.62
NFKB2 Q00653 1/20 0.62
RELA Q04206 1/20 0.62
HDAC6 Q9UBN7 1/20 0.62
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2C19 P33261 1/20 0.60
HTT P42858 1/20 0.60
DYRK1A Q13627 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210774 0.85 RAB9A (0.81) SCDNPC1RAB9AMEN1KMT2A
SCHEMBL16554145 0.83 SCD (0.88) SCDNPC1RAB9AMEN1KMT2A
SCHEMBL213831 0.83 HDAC1 (0.82) GSK3BSCDNPC1RAB9AMEN1
SCHEMBL16562069 0.82 SCD (1.00) SCDNPC1RAB9AMEN1KMT2A
SCHEMBL2820972 0.82 RAB9A (0.69) GSK3BSCDNPC1RAB9AMEN1
SCHEMBL1282877 0.82 ABL1 (0.83) SCDNPC1RAB9AMEN1KMT2A
SCHEMBL6057856 0.81 LCK (0.80) GSK3BSCDNPC1RAB9AMEN1
SCHEMBL6058245 0.81 GSK3B (0.73) GSK3BSCDNPC1RAB9AMEN1
SCHEMBL2759558 0.80 RAB9A (0.71) GSK3BSCDNPC1RAB9AMEN1
SCHEMBL2732073 0.79 RAB9A (0.66) GSK3BSCDNPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
EP-1735319-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-12-27 EP disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 GSK3B 392/4885SCD 1653/4885NPC1 1293/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 GSK3B 445/4885SCD 1721/4885NPC1 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.